These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19026469)

  • 1. Classification models for CYP450 3A4 inhibitors and non-inhibitors.
    Choi I; Kim SY; Kim H; Kang NS; Bae MA; Yoo SE; Jung J; No KT
    Eur J Med Chem; 2009 Jun; 44(6):2354-60. PubMed ID: 19026469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivariate modeling of cytochrome P450 3A4 inhibition.
    Kriegl JM; Eriksson L; Arnhold T; Beck B; Johansson E; Fox T
    Eur J Pharm Sci; 2005 Apr; 24(5):451-63. PubMed ID: 15784335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of CYP3A4 inhibition models: comparisons of machine-learning techniques and molecular descriptors.
    Arimoto R; Prasad MA; Gifford EM
    J Biomol Screen; 2005 Apr; 10(3):197-205. PubMed ID: 15809315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of In Silico Models for Predicting Potential Time-Dependent Inhibitors of Cytochrome P450 3A4.
    Xu M; Lu Z; Wu Z; Gui M; Liu G; Tang Y; Li W
    Mol Pharm; 2023 Jan; 20(1):194-205. PubMed ID: 36458739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A support vector machine approach to classify human cytochrome P450 3A4 inhibitors.
    Kriegl JM; Arnhold T; Beck B; Fox T
    J Comput Aided Mol Des; 2005 Mar; 19(3):189-201. PubMed ID: 16059671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of cytochrome P450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines.
    Yap CW; Chen YZ
    J Chem Inf Model; 2005; 45(4):982-92. PubMed ID: 16045292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Silico Prediction of Cytochrome P450-Drug Interaction: QSARs for CYP3A4 and CYP2C9.
    Nembri S; Grisoni F; Consonni V; Todeschini R
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27294921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The computational model to predict accurately inhibitory activity for inhibitors towards CYP3A4.
    Xie Z; Zhang T; Wang JF; Chou KC; Wei DQ
    Comput Biol Med; 2010; 40(11-12):845-52. PubMed ID: 20951982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5).
    Jones DR; Ekins S; Li L; Hall SD
    Drug Metab Dispos; 2007 Sep; 35(9):1466-75. PubMed ID: 17537872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.
    Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
    J Pharmacol Exp Ther; 1999 Jul; 290(1):429-38. PubMed ID: 10381809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors.
    Jensen BF; Vind C; Padkjaer SB; Brockhoff PB; Refsgaard HH
    J Med Chem; 2007 Feb; 50(3):501-11. PubMed ID: 17266202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
    Roy K; Pratim Roy P
    Eur J Med Chem; 2009 Jul; 44(7):2913-22. PubMed ID: 19128860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding free energies of inhibitors to iron porphyrin complex as a model for Cytochrome P450.
    Lee JY; Kang NS; Kang YK
    Biopolymers; 2012 Apr; 97(4):219-28. PubMed ID: 22113809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems.
    Sevrioukova IF; Poulos TL
    Dalton Trans; 2013 Mar; 42(9):3116-26. PubMed ID: 23018626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QSAR modeling of in vitro inhibition of cytochrome P450 3A4.
    Mao B; Gozalbes R; Barbosa F; Migeon J; Merrick S; Kamm K; Wong E; Costales C; Shi W; Wu C; Froloff N
    J Chem Inf Model; 2006; 46(5):2125-34. PubMed ID: 16995743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.
    Sevrioukova IF; Poulos TL
    J Med Chem; 2013 May; 56(9):3733-41. PubMed ID: 23586711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
    Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
    Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.
    Kaur P; Chamberlin AR; Poulos TL; Sevrioukova IF
    J Med Chem; 2016 May; 59(9):4210-20. PubMed ID: 26371436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.
    Zhang X; Jones DR; Hall SD
    Drug Metab Dispos; 2009 Jan; 37(1):150-60. PubMed ID: 18854379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.